From a retrospective study of 97 and a prospective study of 41 Stage I cutaneous melanomas, it was found that tumor thickness is a better measure of prognosis than is the level of invasion of the tumor. The chance of developing recurrent disease appears to be directly proportional to tumor thickness. Prophylactic lymph node dissection doubled the rate of survival for patients with lesions greater than 1.50 mm thick but had no effect on those with thinner lesions. Thirty-nine per cent of the patients had lesions less than 0.76 mm thick and all survived free of disease for 5 or more years. Six per cent of the tumors that recurred or metastasized were in an intermediate range of 0.76-1.50 mm thick, and no discriminant could be found to separate these 9 lesions with a bad prognosis from the remaining 18 in this group.
T HE ROLE OF PROPHYLACTIC lymph node dissection in -'the treatment of patients with Stage I cutaneous melanoma is still under debate.3 4 A probable explanation for the persistence of this debate is the marked heterogeneity of cutaneous melanoma with variation in size, type of lesion and level of invasion, any of which might alter the prognosis and subsequent need for prophylactic node dissection. In 1969 Clark et al.2 separated melanomas into nodular, superficial spreading and lentigo maligna types and demonstrated that the nodular was the most and the lentigo maligna the least malignant. They also defined four levels of invasion of the dermis and subcutaneous fat and found that prognosis, independent of treatment, was inversely related to the level of invasion. These levels are commonly used to select patients for prophylactic node dissection, restricting such treatment to patients with level III to V lesions. In 1970 we' showed that tumor thickness is a reliable measure of prognosis in cutaneous melanoma and this has recently From The George Washington University School of Medicine, Washington, D.C.
been confirmed by Hansen and McCarten5 and Wanebo et al. 9 The former group also found that prophylactic node dissection is of value when used for patients with melanomas 1.50 mm or thicker but not for patients with thinner lesions. In this study we would like to add a prospective group of 41 patients to our original retrospective series of 97 patients and to compare the usefulness of tumor thickness with Clark's level of invasion in selecting patients for prophylactic lymph node dissection.
Materials and Methods
All patients in this study were free of recurrent or metastatic disease and none had satellite nodules when first seen at the George Washington University Hospital. None of the lesions were of the lentigo malignum type. Their ages ranged from 14 to 79 years (average 39). Twenty were men and 21 women. Seven had lesions of the head and neck; 14 of an extremity; and 20 of the trunk.
Following operation, 17 remained free of disease for 5 or more years, while 24 developed metastatic or recurrent disease. Patients who died of unknown causes, who died in less than 5 years without melanoma and those lost to followup were excluded from the study. Followup was 87% for the prospective group, 92% for the retrospective group and 91% for the combined series. After the publication of our original paper, we discovered that one of the patients with a level IV, 2.50 mm thick lesion had died 5.5 years after surgery, supposedly of a primary bronchogenic carcinoma. Despite repeated attempts, we Though most level II lesions are thin and all level V lesions are thick, there is great variation in thickness for levels III and IV and this has recently been confirmed by others.5'9 Since the chance of developing recurrent disease appears to be directly proportional to tumor thickness and the mean survival following surgery appears to be inversely proportional to tumor thickness,5 this heterogeneity within levels III and IV is a serious defect if the level of invasion is to be used to guide treatment. If the suggestion that all patients with level III to V melanomas should be treated with elective node dissection is followed, and if our patient population is not unique, the following can be expected:
1. Seventeen per cent of patients with level II lesions will not be treated with node dissection but will have lesions 0.76-1.50 mm thick. Though this is in the range for which the value of elective node dissection is still to be proven, one such patient had positive nodes and is alive and free of disease at more than 5 years.
2. Twenty-five per cent of patients with level III lesions will have unnecessary node dissections with lesions less than 0.76 mm thick. We have yet to see such a lesion recur or metastasize.
3. If one wishes to limit node dissections to patients with lesions greater than 1.50 mm thick, for whom node dissections are of proven value, 29% of patients with level III to V lesions will be treated unnecessarily.
Another serious problem in using Clark's levels of invasion is the difficulty in differentiating between an advanced level II and a level III lesion. The difference is somewhat subjective, and several pathologists have commented on this problem.7'8'9 In one collaborative study,8 agreement among the pathologists could only be achieved after instruction by Dr. Clark. By contrast, measurement of tumor thickness is objective, and good agreement among pathologists is to be expected. Hansen and McCarten,5 in a retrospective study of 154 melanomas (50 of head and neck, 36 of trunk and 68 of extremities), also found tumor thickness to be of greater value than level of invasion in selecting patients for prophylactic node dissection. They report that prophylactic lymph node dissection is of value for 575 melanomas 1.50 mm or thicker but not for thinner lesions. Seventy-seven per cent of treated patients survived free of disease for an average of 8 years as compared to 43% for the untreated group (P<0.01). Though their overall study included patients with lentigo maligna melanoma, a group we excluded because of its low degree of malignancy, none of the patients in their treated group of thick melanomas had such a lesion. 6 They only encountered one lethal melanoma less than 1.50 mm thick, while we found 9. This may reflect differences in the rates at which rural Canadians and urban white Washingtonians seek medical care. The more lethal thin melanomas may have metastasized before the patients saw the physicians, thus excluding these patients from the stage I group under study.
